These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 15330217)
1. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Miyake H; Hara I; Eto H Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217 [TBL] [Abstract][Full Text] [Related]
2. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Muramaki M; Miyake H; Yamada Y; Hara I Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065 [TBL] [Abstract][Full Text] [Related]
4. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Miyake H; Muramaki M; Furukawa J; Kurahashi T; Fujisawa M Urology; 2010 Feb; 75(2):454-9. PubMed ID: 19854485 [TBL] [Abstract][Full Text] [Related]
5. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Tumminello FM; Flandina C; Crescimanno M; Leto G Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092 [TBL] [Abstract][Full Text] [Related]
6. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression. Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195 [TBL] [Abstract][Full Text] [Related]
7. [Proteases and prostatic disease: cytosolic cathepsin D]. Gómez Díaz ME; Ruibal-Morell A; Abascal García R Arch Esp Urol; 2001 Mar; 54(2):101-7. PubMed ID: 11341113 [TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related]
9. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Kehinde EO; Maghrebi MA; Anim JT Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443 [TBL] [Abstract][Full Text] [Related]
10. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329 [TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606 [TBL] [Abstract][Full Text] [Related]
14. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829 [TBL] [Abstract][Full Text] [Related]
15. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679 [TBL] [Abstract][Full Text] [Related]
16. Hormonal predictors of prostate cancer. Sofikerim M; Eskicorapci S; Oruç O; Ozen H Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161 [TBL] [Abstract][Full Text] [Related]
17. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154 [TBL] [Abstract][Full Text] [Related]
18. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992 [TBL] [Abstract][Full Text] [Related]
19. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204 [TBL] [Abstract][Full Text] [Related]
20. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Miyake H; Sakai I; Harada K; Hara I; Eto H Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]